ABBOTT LABORATORIES (NYSE:ABT) Files An 8-K Results of Operations and Financial Condition

ABBOTT LABORATORIES (NYSE:ABT) Files An 8-K Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial
Condition

On January25, 2017, Abbott Laboratories announced its results of
operations for the fourth quarter and full year 2016.

Furnished as Exhibit99.1, and incorporated herein by reference,
is the news release issued by Abbott announcing those results. In
that news release, Abbott uses various non-GAAP financial
measures including, among others, net earnings from continuing
operations excluding specified items. These non-GAAP financial
measures adjust for factors that are unusual or unpredictable,
such expenses primarily associated with acquisitions, including
bridge facility fees and other debt-related costs, charges
related to cost reduction initiatives and other expenses,
adjustments to tax expense as a result of the resolution of
various tax positions from prior years, foreign exchange loss
related to Venezuela, expenses related to an adjustment of
Abbotts equity investment in Mylan N.V., a gain on the sale of a
portion of Abbotts position in Mylan stock, a decrease in the
fair value of contingent consideration related to a business
acquisition, and recognition of deferred taxes associated with
the pending disposition of AMO. These non-GAAP financial measures
also exclude intangible amortization expense to provide greater
visibility on the results of operations excluding these costs,
similar to how Abbotts management internally assesses
performance. Abbotts management believes the presentation of
these non-GAAP financial measures provides useful information to
investors regarding Abbotts results of operations as these
non-GAAP financial measures allow investors to better evaluate
ongoing business performance. Abbotts management also uses these
non-GAAP financial measures internally to monitor performance of
the businesses. Abbott, however, cautions investors to consider
these non-GAAP financial measures in addition to, and not as a
substitute for, financial measures prepared in accordance with
GAAP.

Item 9.01 Financial Statements and
Exhibits

ExhibitNo.		Exhibit
99.1		Press Release dated January25, 2017 (furnished to Item 2.02).

About ABBOTT LABORATORIES (NYSE:ABT)
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Nutrition Products segment includes the sales of a line of adult and pediatric nutritional products. The Diagnostic Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products. ABBOTT LABORATORIES (NYSE:ABT) Recent Trading Information
ABBOTT LABORATORIES (NYSE:ABT) closed its last trading session down -0.03 at 40.31 with 7,773,693 shares trading hands.